NZ587829A - Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts - Google Patents

Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Info

Publication number
NZ587829A
NZ587829A NZ587829A NZ58782909A NZ587829A NZ 587829 A NZ587829 A NZ 587829A NZ 587829 A NZ587829 A NZ 587829A NZ 58782909 A NZ58782909 A NZ 58782909A NZ 587829 A NZ587829 A NZ 587829A
Authority
NZ
New Zealand
Prior art keywords
cancer
leukemia
small cell
benzimidazol
methylpiperazin
Prior art date
Application number
NZ587829A
Other languages
English (en)
Inventor
Danielle Giron
Walter Hammerschmidt
Philippe Piechon
Johanne Polasek
Andreas Schreiner
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40622140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ587829(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to NZ600887A priority Critical patent/NZ600887A/xx
Publication of NZ587829A publication Critical patent/NZ587829A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ587829A 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts NZ587829A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ600887A NZ600887A (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3774608P 2008-03-19 2008-03-19
PCT/EP2009/053222 WO2009115562A2 (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Publications (1)

Publication Number Publication Date
NZ587829A true NZ587829A (en) 2012-08-31

Family

ID=40622140

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ587829A NZ587829A (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
NZ600887A NZ600887A (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ600887A NZ600887A (en) 2008-03-19 2009-03-18 Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts

Country Status (24)

Country Link
US (1) US8563556B2 (enExample)
EP (1) EP2257544B1 (enExample)
JP (1) JP2011515370A (enExample)
KR (1) KR20100137517A (enExample)
CN (1) CN101970425B (enExample)
AR (1) AR070924A1 (enExample)
AU (1) AU2009227003B2 (enExample)
BR (1) BRPI0909762A2 (enExample)
CA (1) CA2718076A1 (enExample)
CL (1) CL2009000651A1 (enExample)
CO (1) CO6321253A2 (enExample)
EC (1) ECSP10010555A (enExample)
IL (1) IL208020A0 (enExample)
MA (1) MA32230B1 (enExample)
MX (1) MX2010010152A (enExample)
MY (1) MY150554A (enExample)
NZ (2) NZ587829A (enExample)
PE (1) PE20091628A1 (enExample)
PH (2) PH12012502569A1 (enExample)
RU (1) RU2497820C2 (enExample)
SG (1) SG188919A1 (enExample)
TW (1) TWI426072B (enExample)
WO (1) WO2009115562A2 (enExample)
ZA (1) ZA201006263B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
WO2011128403A1 (en) 2010-04-16 2011-10-20 Novartis Ag Organic compound for use in the treatment of liver cancer
NZ602807A (en) 2010-04-16 2014-02-28 Novartis Ag 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
SG192962A1 (en) 2011-03-17 2013-09-30 Novartis Ag Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
CN103547315A (zh) 2011-05-19 2014-01-29 诺华股份有限公司 用于治疗腺样囊性癌的4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮
IN2014DN02060A (enExample) 2011-09-15 2015-05-15 Novartis Ag
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
EP2809312A1 (en) 2012-01-31 2014-12-10 Novartis AG Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
CR20170410A (es) 2015-03-10 2017-11-08 Aduro Biotech Inc Composiciones y métodos para activar la señalización dependiente del "estimulador del gen interferon"
HUE055469T2 (hu) 2015-07-29 2021-11-29 Novartis Ag A LAG-3 elleni antitest molekulákat tartalmazó kombinált terápiák
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60132937T2 (de) * 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
US7470709B2 (en) * 2002-08-23 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
AU2003290699B2 (en) * 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
EP2762475A1 (en) * 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Pharmaceutically acceptable salts of quinolinone compounds and their medical use
EP1718306A2 (en) * 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
EP2301546B1 (en) * 2005-01-27 2014-09-10 Novartis AG Treatment of metastasized tumors
JP2008542289A (ja) * 2005-05-23 2008-11-27 ノバルティス アクチエンゲゼルシャフト ４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１イル）−１ｈ−ベンズイミダゾール−２−イル］−１ｈ−キノリン−２−オン乳酸塩の結晶およびその他の形態
WO2007064719A2 (en) * 2005-11-29 2007-06-07 Novartis Ag Formulations of quinolinones
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona

Also Published As

Publication number Publication date
BRPI0909762A2 (pt) 2018-04-03
SG188919A1 (en) 2013-04-30
WO2009115562A3 (en) 2009-11-26
PH12012502569A1 (en) 2015-09-21
CN101970425A (zh) 2011-02-09
RU2010142396A (ru) 2012-04-27
CL2009000651A1 (es) 2010-07-19
CA2718076A1 (en) 2009-09-24
PE20091628A1 (es) 2009-11-19
MY150554A (en) 2014-01-30
ECSP10010555A (es) 2010-11-30
AR070924A1 (es) 2010-05-12
EP2257544B1 (en) 2014-12-03
US8563556B2 (en) 2013-10-22
NZ600887A (en) 2013-10-25
AU2009227003A1 (en) 2009-09-24
JP2011515370A (ja) 2011-05-19
MA32230B1 (fr) 2011-04-01
EP2257544A2 (en) 2010-12-08
TW201000463A (en) 2010-01-01
WO2009115562A2 (en) 2009-09-24
TWI426072B (zh) 2014-02-11
KR20100137517A (ko) 2010-12-30
CN101970425B (zh) 2014-04-16
RU2497820C2 (ru) 2013-11-10
PH12012502568A1 (en) 2014-10-27
AU2009227003B2 (en) 2013-03-14
MX2010010152A (es) 2010-10-25
IL208020A0 (en) 2010-12-30
ZA201006263B (en) 2011-05-25
HK1147492A1 (en) 2011-08-12
CO6321253A2 (es) 2011-09-20
US20110021536A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
NZ587829A (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
JP2011515370A5 (enExample)
HRP20230400T1 (hr) Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1
NZ593114A (en) Compounds comprising benzimidazolyl, pyrimidinyl, and pyridinyl moieties which are useful as protein kinase inhibitors
PH12014500883A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
RU2018100142A (ru) Гетероциклические соединения, эффективные для ингибирования киназы
NZ627454A (en) 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors
PH12012500965A1 (en) Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2, or pdgf-r kinase activity
PE20090506A1 (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
NZ608285A (en) Manufacturing process for pyrimidine derivatives
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MY187446A (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
ME02254B (me) Derivati hidroksamske kiseline
MY153727A (en) Pyridazinone derivatives
JP2017528475A5 (enExample)
MX368066B (es) Derivados de quinazolin-4-ona sustituida.
PE20180530A1 (es) Derivados de amidas policiclicas como inhibidores de cdk9
GEP20197050B (en) Solid state forms of fused heteroaromatic pyrrolidinones
PE20091468A1 (es) DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
IN2012DN01983A (enExample)
PH12012500797A1 (en) Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
JP2017526662A5 (enExample)
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX360912B (es) Compuestos de piridopirimidina sustituida y su uso como inhibidores de tirosina cinasa 3 similar a fms.
NZ714747A (en) Compounds of ‘3-(5-substituted oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester’, process and applications thereof

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 MAR 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20130114

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 MAR 2017 BY CPA GLOBAL

Effective date: 20160205

LAPS Patent lapsed